BioCentury
ARTICLE | Clinical News

AMY-101 regulatory update

November 17, 2014 8:00 AM UTC

FDA granted Orphan Drug designation to AMY-101 to treat paroxysmal nocturnal hemoglobinuria (PNH). In 2015, the company plans to start clinical testing of the complement 3 (C3) inhibitor. In August, t...